ACELRX PHARMACEUT. DL-01 (R5XA) — Working Capital to Net Assets Ratio
ACELRX PHARMACEUT. DL-01 (R5XA) has a Working Capital to Net Assets ratio of 100.3% as of December 2025. Working capital of €17.09 Million (current assets of €20.90 Million minus current liabilities of €3.81 Million) is measured against net assets of €17.04 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See R5XA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
ACELRX PHARMACEUT. DL-01 Working Capital to Net Assets (2021–2025)
This chart shows how ACELRX PHARMACEUT. DL-01's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 100.3%, reflecting working capital of €17.09 Million against net assets of €17.04 Million EUR. For the complete balance sheet picture, see ACELRX PHARMACEUT. DL-01 assets under control.
Annual Working Capital to Net Assets for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for ACELRX PHARMACEUT. DL-01 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check asset resilience ratio of ACELRX PHARMACEUT. DL-01 to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 100.3% | €17.09 Million | €17.04 Million | €20.90 Million | €3.81 Million | ▲ +15.7 pp |
| 2024 | 84.6% | €6.77 Million | €8.00 Million | €9.42 Million | €2.65 Million | ▲ +34.5 pp |
| 2023 | 50.1% | €7.06 Million | €14.11 Million | €11.58 Million | €4.51 Million | ▲ +0.6 pp |
| 2022 | 49.5% | €10.80 Million | €21.81 Million | €24.57 Million | €13.77 Million | ▲ +138.6 pp |
| 2021 | -89.1% | €31.98 Million | €-35.89 Million | €50.49 Million | €18.51 Million | — |